CD133 expression is associated with less DNA repair, better response to chemotherapy, and survival in ER-positive/ER-negative breast cancer

被引：0
|
作者：
Sato, Takumi
Oshi, Masanori
Lee, Jing
Roy, Arya M.
Chida, Kohei
Endo, Itaru
Obayashi, Masato
Takabe, Kazuaki
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-2520
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2520
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phosphorylation of p90RSK is associated with increased response to neoadjuvant chemotherapy in ER-positive breast cancer
    Moon, Hyeong-Gon
    Yi, Jae Kyo
    Kim, Hee Sung
    Lee, Hea Young
    Lee, Kyung-Min
    Yi, Minju
    Ahn, Sookyung
    Shin, Hee-Chul
    Ju, Ji-hyun
    Shin, Incheol
    Han, Wonshik
    Noh, Dong-Young
    BMC CANCER, 2012, 12
  • [42] Phosphorylation of p90RSK is associated with increased response to neoadjuvant chemotherapy in ER-positive breast cancer
    Hyeong-Gon Moon
    Jae Kyo Yi
    Hee Sung Kim
    Hea Young Lee
    Kyung-Min Lee
    Minju Yi
    Sookyung Ahn
    Hee-Chul Shin
    Ji-hyun Ju
    Incheol Shin
    Wonshik Han
    Dong-Young Noh
    BMC Cancer, 12
  • [43] GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer
    Miyake, Tomohiro
    Nakayama, Takahiro
    Naoi, Yasuto
    Yamamoto, Noriaki
    Otani, Yoko
    Kim, Seung J.
    Shimazu, Kenzo
    Shimomura, Atsushi
    Maruyama, Naomi
    Tamaki, Yasuhiro
    Noguchi, Shinzaburo
    CANCER SCIENCE, 2012, 103 (05): : 913 - 920
  • [44] Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer
    L S Rigter
    C E Loo
    S C Linn
    G S Sonke
    E van Werkhoven
    E H Lips
    H A Warnars
    P K Doll
    A Bruining
    I A Mandjes
    M J Vrancken Peeters
    J Wesseling
    K G Gilhuijs
    S Rodenhuis
    British Journal of Cancer, 2013, 109 : 2965 - 2972
  • [45] Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer
    Rigter, L. S.
    Loo, C. E.
    Linn, S. C.
    Sonke, G. S.
    van Werkhoven, E.
    Lips, E. H.
    Warnars, H. A.
    Doll, P. K.
    Bruining, A.
    Mandjes, I. A.
    Peeters, M. J. Vrancken
    Wesseling, J.
    Gilhuijs, K. G.
    Rodenhuis, S.
    BRITISH JOURNAL OF CANCER, 2013, 109 (12) : 2965 - 2972
  • [46] The EndoPredict Score Is a Response Predictor for Neoadjuvant Chemotherapy in ER-Positive, HER2-Negative Breast Cancer.
    Brase, J. C.
    Gehrmann, M. C.
    Petry, C.
    Weber, K. E.
    Schmidt, M.
    Koelbl, H.
    Brauch, H.
    Schwab, M.
    Mueller, V.
    Jaenicke, F.
    Rody, A.
    Kaufmann, M.
    Filipits, M.
    Gnant, M.
    Denkert, C.
    Loibl, S.
    von Minckwitz, G.
    Kronenwett, R.
    CANCER RESEARCH, 2011, 71
  • [47] Differential Effects of EGCG, a Green Tea Antioxidant, on Vascular Endothelial Growth Factor (VEGF) Expression and Proliferation in Cultured ER-positive and ER-negative Human Breast Cancer Cells
    Young, Emily
    Wells, Jeremy
    Tucker, Kevan B.
    Chawla, Simran
    Gu, Jian-Wei
    FASEB JOURNAL, 2009, 23
  • [48] Subcellular Localisation of Dicer Expression Correlates with Survival and Tumour Subtype in ER-Positive Breast Cancer
    Le Quesne, J.
    Warren, J.
    Howat, W.
    Blows, F.
    Pharoah, P.
    Caldas, C.
    JOURNAL OF PATHOLOGY, 2011, 224 : S21 - S21
  • [49] Identification of key differentially expressed genes between ER-positive/HER2-negative breast cancer and ER-negative/HER2-negative breast cancer using integrated bioinformatics analysis
    Gan, Siyuan
    Dai, Haixia
    Li, Rujia
    Liu, Wang
    Ye, Ruifang
    Ha, Yanping
    Di, Xiaoqing
    Hu, Wenhua
    Zhang, Zhi
    Sun, Yanqin
    GLAND SURGERY, 2020, 9 (03) : 661 - 675
  • [50] Reply to: Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer
    Goldhirsch, A.
    Coates, A. S.
    ANNALS OF ONCOLOGY, 2014, 25 (03) : 755 - 755
12345